UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August, 2015
Commission File Number
Novogen
Limited
(Translation of registrants name into English)
16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ¨ No þ
If yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Novogen Limited (Registrant)
Lionel Mateo
Lionel Mateo
Company Secretary
Date 5 August 2015
|
|
|
ASX:NRT
NASDAQ:NVGN
Novogen Ltd (Company)
ABN 37 063 259 754
Capital Structure
Ordinary Shares on issue:
424 M
Board of Directors
Ian Phillips MNZM
Interim Chairman
Mr Iain Ross Director
Acting CEO
Steve Coffey Non-Executive Director
John OConnor
Non-Executive Director
Prof Peter Gunning Non-Executive Director
Bryce Carmine
Non-Executive Director |
|
MARKET RELEASE 5 August 2015
NOVOGEN STRENGTHENS POSITION IN ATM PLATFORM BY LODGING NEW
PATENTS Sydney, August 5, 2015 US-Australian
drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN) today announced it had taken steps to augment the Companys dominant intellectual property position on its anti-tropomyosin (ATM) technology platform with the lodgement of final
specifications for two new patents covering its pioneering platform. According to
Group Vice President of Drug Discovery and Development, Dr Andrew Heaton, these patent specifications cover a wide range of novel ATM compounds, including the Companys lead ATM drug candidate, Anisina. These patents add to the two previous ATM
patents lodged in May 2015. The active ingredient of Anisina is a small molecule
targeting a protein component of the actin microfilament called tropomyosin (Tpm3.1), which researchers have shown to be essential for tumor cell survival in vitro. Additional in vitro studies have shown that inhibiting the function of Tpm3.1
with this family of novel ATM compounds causes tumor cell death across a broad range of cancer cell types. Pending the outcome of its manufacturing and toxicology programs, Anisina is expected to start Phase 1 clinical trials (first in human) in
2016. Over the past 18 months Novogen scientists have perfected the design and
synthesis of extensive libraries of novel ATMs, using the Companys VAL-ID (Versatile Approach to Library based Iterative Design) approach, Dr Heaton said.
These final patent specifications represent two new families of ATMs and expand the structural diversity from the earlier ATM patents. The new patents
focus on a range of new chemical libraries that are capable of enhanced specificity for the cancer-associated tropomyosin Tpm3.1, facilitating rapid lead identification. |
These additional patent specifications are a significant part of the Companys R&D commitment to the technology
platform and protect a critical asset.
The patents enable Novogen to seamlessly commence a scale-up manufacturing process and to own that
process outright. We have already commenced the large-scale manufacture of Anisina and have successfully produced multi-kilogram amounts to a standard suitable for advanced pre-clinical toxicity screening to allow us to conduct multiple clinical
studies, Dr Heaton concluded.
About Novogen
Novogen is a public, Australian-US drug development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen
group includes US-based, CanTx Inc., a joint venture company with Yale University. Novogen has two drug technology platforms [the superbenzopyrans (SBPs) and anti-tropomyosins (ATMs)] yielding drug candidates that are first-in-class with potential
application across a range of oncology applications. Given the encouraging data from in vitro and in vivo pre-clinical Proof-of-Concept studies in the field of Oncology, our immediate focus is to advance our lead Oncology drug candidates pending
successful completion of their respective toxicology programs. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the potential clinical indications being
pursued, with the ultimate objective of employing both technologies as a unified approach to therapy.
For more information, please visit
www.novogen.com
Media Enquiries
Kym Robins
Marketing and Communications Manager
Novogen Group
E: Kym.Robins@novogen.com
+61 (0) 2 9472 4109
Forward Looking Statement
This press release
contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such
words as expects, appear, intends, hopes, anticipates, believes, could, should, would, may, target,
evidences and estimates, and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Companys
drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Companys drug development program, including, but not limited to, Anisina and any other statements that are not historical
facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the
Companys drug components, including, but not limited to, Anisina, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Companys drug
compounds, including, but not limited to, Anisina that could slow or prevent products coming to market, the uncertainty of patent protection for the Companys intellectual property or trade secrets, including, but not limited to, the
intellectual property relating to, Anisina, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements
are based on managements current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those
forward-looking statements as a prediction of actual future results.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Apr 2023 to Apr 2024